Scientists funded by the National Institutes of Health have found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus. Although the Marburg and Ravn viruses are less familiar than Ebola virus, both can resemble Ebola in symptoms and outcomes in people, and both lack preventive and therapeutic countermeasures.
The study involved giving the animals a therapeutic candidate, MR191-N, which is a monoclonal antibody derived from a person who survived Marburg disease. Monoclonal antibodies are immune system fighters designed to bind to a specific part of an invading virus or bacterium to treat disease. The authors report that two doses of MR191-N were able to confer protection of up to 100 percent when treatment was started up to 5 days post infection. Prior studies of different experimental Marburg treatments involved daily dosing for 7 and 14 days, respectively, with treatment beginning closer to the time of infection.
The study was led by scientists at the University of Texas Medical Branch Galveston National Laboratory and Mapp Biopharmaceutical, Inc., and included collaborators from Vanderbilt University Medical Center, the University of Natural Resources and Life Sciences in Austria, and The Scripps Research Institute. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) provided project funding.
The researchers are now working with NIAID's preclinical services group to perform the additional safety testing necessary to advance the monoclonal antibody treatment to initial human clinical studies. Public health workers learned during the 2014-15 Ebola outbreak in West Africa that lack of available treatment options kept diseased and at-risk people away from treatment centers, making disease tracking and outbreak containment more difficult. They fear the same situation would develop in a large-scale Marburg outbreak.
C Mire et al. Therapeutic treatment of Marburg and Ravn virus disease in nonhuman primates with a human monoclonal antibody. Science Translational Medicine DOI: 10.1126/scitranslmed.aai8711 (2017).
Tina M. Parker, DVM, MScPH, of NIAID's Office of Biodefense, Research Resources and Translational Research, is available to comment on this study.
To schedule interviews, please contact Ken Pekoc, (301) 402-1663, email@example.com.
This research was supported by the following NIH grants: SB1AI082744, U19AI109762, U19AI109711, and UC7AI094660. Continued development will be supported through a Task Order awarded in 2017 under the Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA) Centers for Innovation in Advanced Development and Manufacturing (CIADM) program.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.